Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05049486
Other study ID # London North West NHS Trust
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2017
Est. completion date March 26, 2018

Study information

Verified date April 2018
Source London North West Healthcare NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high-resolution anatomical MRI sequences and diffusion tensor imaging (DTI). DTI is a non-invasive technique sometimes described as fiber tractography that enables visualization of the pathways and integrity of nerves. In this feasibility study, we plan to use DTI to assess the sacral plexus and its peripheral nerves. A model will be constructed by superimposing SNS lead from a CT scan onto the DTI imaging to map out the electrode position. It is hoped that this study will lead to a better understanding of both therapeutic and adverse stimulation effects and enable patient-specific adjustments of stimulation parameters.


Description:

Patients who have had successful temporary SNS and awaiting permanent SNS will be approached. An assessment will be made to determine whether the patient meets the inclusion/exclusion criteria. Patients will be given a consent form to sign. The investigators will recruit from the outpatient clinic a total of ten patients for this study. A physical examination will be performed as per standard practice. Patients will be asked to fill in questionnaires probing the severity of faecal incontinence symptoms. Included questionnaires are ICIQ-B4, Wexner's and St Mark's. Incontinence score (see appendix). It will also evaluate any existing pain symptoms. The patient will undergo an MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed at Mount Vernon Hospital over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing. A surgical procedure (implant of SNS) will be performed as per standard practice. Briefly, an antibiotic will be given at induction of anesthesia prior to skin incision. All types of equipment for SNS implantation will be soaked in antibiotic solution (gentamicin 80mg in 500ml of normal saline or equivalent). Under general anesthesia without neuromuscular junction blockade and the patient in prone position, a permanent quadripolar lead (model 3889) will be inserted aiming to observe contraction of the anus and/or toe flexion, which are signs to confirm that the lead is nearby third sacral nerve root. The lead position will be confirmed by an x-ray and the lead will be connected to an implantable neurostimulator which will be placed under the skin but deep enough in the upper outer area of the buttock region. The procedure will be performed according to the manufacturer's manual as per our clinical standard. After the implantation, patients will be given one generic starting program to start the therapy. Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed (see details below). After the scan, a clinician will test stimulation settings systematically to find an optimal program. Briefly, as the lead as 4 electrodes, each electrode will be tested, followed by a combination of electrodes. The patient's subjective responses (type and site of sensation, if there is any pain/discomfort site and nature, a degree of pain using a Lickert scale,) will be recorded. The investigators will try and obtain motor response if possible, at the level when patients' anus contracts slightly if this is achievable without causing significant distress and pain to the patients. This is also a routine process and the clinician will note if there is any specific setting that causes adverse pain and identify settings that are comfortable and give stimulation sensation around the anus. The computational model will be done in a computer laboratory and the record will be compared and evaluated for any clinical relevance. The same set of questionnaires used during the baseline evaluation will be repeated at follow-ups, as per routine care.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 26, 2018
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who are psychologically stable and suitable for intervention and able to provide informed consent - Patients with symptoms of faecal incontinence for solid or liquid stool - Patients who have had successful outcome from temporary SNS - Patients who are willing and competent to fill in questionnaires and undergo an extra CT and MRI scan during the study Exclusion Criteria: - Patients who are claustrophobic to undertake MRI scan - Patients who had previous devices implanted that may be magnetically, electrically, mechanically activated or affected by MRI scan - Pregnant patients - Patients who are breastfeeding - Patients who are psychologically unstable and unsuitable for intervention and unable to provide informed consent - Patients who did not successfully pass the trial of SNS temporary SNS)

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
CT scan
Patients will undergone a pelvic CT scan.

Locations

Country Name City State
United Kingdom London North West NHS Trust Harrow

Sponsors (2)

Lead Sponsor Collaborator
London North West Healthcare NHS Trust Medtronic

Country where clinical trial is conducted

United Kingdom, 

References & Publications (6)

Cotterill N, Norton C, Avery KN, Abrams P, Donovan JL. A patient-centered approach to developing a comprehensive symptom and quality of life assessment of anal incontinence. Dis Colon Rectum. 2008 Jan;51(1):82-7. Epub 2007 Nov 15. — View Citation

Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993 Jan;36(1):77-97. Review. — View Citation

Maeda Y, Lundby L, Buntzen S, Laurberg S. Outcome of sacral nerve stimulation for fecal incontinence at 5 years. Ann Surg. 2014 Jun;259(6):1126-31. doi: 10.1097/SLA.0b013e31829d3969. — View Citation

Maeda Y, Lundby L, Buntzen S, Laurberg S. Suboptimal outcome following sacral nerve stimulation for faecal incontinence. Br J Surg. 2011 Jan;98(1):140-7. doi: 10.1002/bjs.7302. Epub 2010 Oct 27. — View Citation

Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999 Jan;44(1):77-80. — View Citation

van der Jagt PK, Dik P, Froeling M, Kwee TC, Nievelstein RA, ten Haken B, Leemans A. Architectural configuration and microstructural properties of the sacral plexus: a diffusion tensor MRI and fiber tractography study. Neuroimage. 2012 Sep;62(3):1792-9. d — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Implanting a lead around a nerve for finer details of tissues surrounding a sacral nerve stimulation lead. Size and distance of the sacral nerves from the implanted lead measured in millimetres (mm). 12 months
Secondary Stimulation of the sacral nerve using computational model induced electrical current to establish therapeutic range of SNS Patient's sensation of stimulation will be measured in amplitude (reported in voltage) shown in the standard remote control during the patient stimulation. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04918329 - Functional Digestive Disorders Observatory
Completed NCT02292628 - Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence Phase 1/Phase 2
Recruiting NCT04612569 - Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
Completed NCT02782364 - Evaluation of the Fast Fill Technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter
Withdrawn NCT03257332 - Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
Completed NCT03261622 - Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective N/A
Recruiting NCT03969069 - Assessment of Faecal Incontinence With MAPLe
Recruiting NCT05245565 - Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer
Completed NCT03078634 - The Multi-disciplinary Treatment of Functional Gut Disorders Study N/A
Recruiting NCT05900726 - Pelvipower for Faecal Incontinence N/A
Recruiting NCT05550675 - Prospective Database of Factors Associated With Faecal vs. Double Incontinence in Patients Referred for High Resolution Anorectal Manometry.
Recruiting NCT04657588 - Controlling Faecal Incontinence With a Novel Anal Device: a Cost-effectiveness Trial N/A
Active, not recruiting NCT04262609 - Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy
Completed NCT05016453 - Long-term Efficacy of Percutaneous Tibial Nerve Stimulation Applied to Patients With Faecal Incontinence.
Completed NCT04007250 - FENIX™ Continence Restoration System Registry
Completed NCT02349334 - UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence Phase 3
Recruiting NCT06143072 - CArE for OAsI Study: Care Pathways and Anorectal Evaluation for OASI Associated Incontinence
Recruiting NCT04276350 - Efficacy of Acupuncture as a Treatment for Faecal Incontinence N/A
Completed NCT01656720 - A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period Phase 2
Withdrawn NCT00420797 - A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence Phase 3